In breast cancers, two PARP inhibitors, olaparib and talazoparib, were recently approved in germline BRCA mutation (gBRCAm) carriers for the treatment of metastatic HER2-negative breast cancer based on both the OlympiAD [75] and EMBRACA [76] trials, respectively. Here, ERBB2 is linked to breast carcinoma.